{
    "clinical_study": {
        "@rank": "165018", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain\n      alcohol) when they are given together."
        }, 
        "brief_title": "A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to one of the following three regimens:\n\n      Regimen 1: 1592U89 alone. Regimen 2: pure grain alcohol diluted in orange juice. Regimen 3:\n      1592U89 plus pure grain alcohol diluted in orange juice. Treatment is administered weekly\n      for 3 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Local treatment for Kaposi's sarcoma.\n\n          -  Prophylactic treatment for opportunistic infections.\n\n        Patients must have:\n\n          -  HIV-1 infection.\n\n          -  CD4+ lymphocyte count >= 200 cells/microliter within 14 days prior to study drug\n             administration.\n\n          -  No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the\n             1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition.\n\n        Prior Medication:\n\n        Allowed:\n\n        Local treatment for Kaposi's sarcoma.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n        Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior\n             to study drug administration and until 12 hours after study drug administration on\n             each dosing day.\n\n          -  Immunomodulators, such as systemic corticosteroids, interleukins and interferons.\n\n          -  Cytotoxic chemotherapeutic agents.\n\n          -  Acute treatment for opportunistic infections.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n        Radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Documented history of alcoholism.\n\n          -  History of clinically relevant hepatitis or pancreatitis within 6 months prior to\n             study drug administration.\n\n          -  History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside\n             analogs.\n\n          -  Participation in another research study within the past month.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Cytotoxic chemotherapeutic agents within six weeks prior to study drug\n             administration.\n\n          -  Immunomodulating agents within six weeks prior to study drug administration.\n\n          -  Treatment with the following within 2 weeks prior to study drug administration:\n\n          -  acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium\n             valproate, or valacyclovir.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Radiation therapy within 6 weeks prior to study drug administration.\n\n        1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer\n        or 1 glass of wine or 1 oz of liquor).\n\n          -  Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by >\n             one month abstinence).\n\n          -  Total abstinence from alcohol use.\n\n          -  Positive breath alcohol test upon arrival at the study center prior to any dosing\n             day."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002198", 
            "org_study_id": "238F", 
            "secondary_id": "CNAA 1010"
        }, 
        "intervention": {
            "intervention_name": "Abacavir sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ethanol", 
                "Abacavir"
            ]
        }, 
        "keyword": [
            "Drug Interactions", 
            "Antiviral Agents", 
            "Ethanol", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wilmington", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28412"
                }, 
                "name": "PPD Development, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002198"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1997"
    }, 
    "geocoordinates": {
        "PPD Development, Inc": "34.226 -77.945"
    }
}